Search results for: Real World Evidence (RWE)
Filter search results
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
…lifecycle, when designing Phase 3 (or even earlier, for products with adaptive development designs), to inform evidence generation for payers’ submissions and post-launch real-world use. Payers and patients need to…
Socio-Economic Value of Adult Immunisation Programmes
18 April 2024
…investment in the process. Expand and develop the evidence base for the value of adult immunisation programmes There are significant gaps in evidence regarding the broader elements of the value…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
A new OHE Research Paper reviews a recent report on cancer pricing published by the World Health Organization. The authors argue that the report fails to promote mechanisms that are…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by the 2018 Seventieth World…
OHE’s 50th Celebration: Publications on Tuberculosis Show Constancy and Change
23 August 2012
…Anderson, L. and Abubakar, I. (2012) Tuberculosis in the UK: 2012 report. London: Health Protection Agency. [3] World Health Organisation. (2012) Tuberculosis. Fact Sheet 104. Geneva: World Health Organisation. …
Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
1 June 2020
…The report finds that the pharmaceutical industry will be a key partner in realising the Government’s ambition and based upon evidence from a range of similar countries identifies the most…
Access to Orphan Drugs in the EU
21 October 2010
…examines: the standards of evidence and the criteria for P&R decisions, the availability of access before full licensing approval, and requirements for studies after the drug is available on the…
New Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
7 March 2017
Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the 2016 ICER Membership Policy…
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
1 March 2017
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and value. Special attention is…